Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LENZ
stocks logo

LENZ

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.957
+107.97%
--
--
-0.902
+70.28%
--
--
-0.767
+44.81%
Estimates Revision
The market is revising Upward the revenue expectations for LENZ Therapeutics, Inc. (LENZ) for FY2025, with the revenue forecasts being adjusted by 41.83% over the past three months. During the same period, the stock price has changed by -33.54%.
Revenue Estimates for FY2025
Revise Upward
up Image
+41.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.68%
In Past 3 Month
Stock Price
Go Down
down Image
-33.54%
In Past 3 Month
Wall Street analysts forecast LENZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LENZ is 57.60 USD with a low forecast of 52.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast LENZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LENZ is 57.60 USD with a low forecast of 52.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.900
sliders
Low
52.00
Averages
57.60
High
67.00
Current: 27.900
sliders
Low
52.00
Averages
57.60
High
67.00
BofA
Jason Gerberry
Buy
maintain
$44 -> $53
2025-08-03
Reason
BofA
Jason Gerberry
Price Target
$44 -> $53
2025-08-03
maintain
Buy
Reason
BofA analyst Jason Gerberry raised the firm's price target on Lenz Therapeutics to $53 from $44 and keeps a Buy rating on the shares. The firm cites the company's Vizz FDA approval and Q2 report the target increase. It believes Lenz's peak sales opportunity for Vizz is being underappreciated at current share levels.
Citi
Buy
maintain
$49 -> $52
2025-08-01
Reason
Citi
Price Target
$49 -> $52
2025-08-01
maintain
Buy
Reason
Citi raised the firm's price target on Lenz Therapeutics to $52 from $49 and keeps a Buy rating on the shares after the FDA approved Vizz a week earlier than the action date. The firm says Lenz has a week "head-start" to start commercialization of the drug.
H.C. Wainwright
NULL -> Buy
upgrade
$38 -> $48
2025-07-28
Reason
H.C. Wainwright
Price Target
$38 -> $48
2025-07-28
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Lenz Therapeutics to $48 from $38 and keeps a Buy rating on the shares. The firm sees positive key opinion leader sentiment for LNZ100, a daily eye drop for presbyopia, heading into the August 8 FDA action date.
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$30
2025-04-16
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$30
2025-04-16
Reiterates
Strong Buy
Reason
Piper Sandler
Biren Amin
Buy
Maintains
$38 → $51
2025-04-14
Reason
Piper Sandler
Biren Amin
Price Target
$38 → $51
2025-04-14
Maintains
Buy
Reason
Piper Sandler analyst Biren Amin assumed coverage of Lenz Therapeutics (LENZ) with an Overweight rating with a price target of $51, up from $38, on the potential of LNZ100, an acelidine-based topical eyedrop for presbyopia, which affects about 128M individuals in the U.S. With the NDA accepted last October and a PDUFA assigned for August 8, 2025, LNZ100 is on track to launch in Q4 2025. The firm believes LNZ100 has a best-in-indication profile, superior to AbbVie's (ABBV) Vuity and Tenpoint's Bramichol. Piper's model estimates U.S. sales of $58M in 2026, growing to $592M by 2035.
Citigroup
Yigal Nochomovitz
Strong Buy
Maintains
$44 → $47
2025-03-20
Reason
Citigroup
Yigal Nochomovitz
Price Target
$44 → $47
2025-03-20
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for LENZ Therapeutics Inc (LENZ.O) is -8.83, compared to its 5-year average forward P/E of -10.56. For a more detailed relative valuation and DCF analysis to assess LENZ Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.56
Current PE
-8.83
Overvalued PE
-8.34
Undervalued PE
-12.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.52
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-5.55
Undervalued EV/EBITDA
-11.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
51.00
Current PS
0.00
Overvalued PS
97.93
Undervalued PS
4.08
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LENZ News & Events

Events Timeline

(ET)
2025-12-01
08:40:00
LENZ and Lotus Submit NDA for VIZZ to Treat Presbyopia in South Korea
select
2025-11-05 (ET)
2025-11-05
08:02:17
Lenz Therapeutics announces Q3 earnings per share of 59 cents, below consensus estimate of 69 cents.
select
2025-09-30 (ET)
2025-09-30
08:17:18
Lenz Therapeutics Reveals VIZZ Now Available for Purchase in the U.S.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02NASDAQ.COM
PinnedLotus Pharma, Partner of LENZ Therapeutics, Pursues Approval for VIZZ to Address Presbyopia in South Korea

  • NDA Submission for VIZZ: LENZ Therapeutics' partner, Lotus Pharmaceutical, has submitted a New Drug Application in South Korea for VIZZ, a treatment for presbyopia, supported by positive Phase 3 trial data.

  • VIZZ's Mechanism and Efficacy: VIZZ is a preservative-free eye drop that improves near vision by temporarily constricting the pupil, showing significant improvement within 30 minutes and lasting up to 10 hours in clinical trials.

  • Commercialization Agreement: The NDA submission follows a May 2025 agreement between LENZ and Lotus Pharma for the commercialization of VIZZ in South Korea and several Southeast Asian countries, with potential milestone payments and royalties for LENZ.

  • Market Status: VIZZ was previously approved in the U.S. for presbyopia treatment in July, while LENZ's stock closed at $30.40, reflecting a 30.40% decrease.

[object Object]
Preview
4.0
12-01TipRanks
Top Analysts Recommend 3 Best Stocks to Purchase as of December 1, 2025

  • Top Analyst Ratings: Recent updates from top Wall Street analysts highlight three stocks—Kratos Defense, LENZ Therapeutics, and Spyre Therapeutics—that have received Strong Buy ratings, indicating solid upside potential.

  • Kratos Defense (KTOS): The stock, which focuses on military drones and national security technologies, has a Buy rating with a price target of $105, suggesting a potential upside of about 31.70%.

  • LENZ Therapeutics (LENZ): This clinical-stage biotech company, developing eye-drop treatments, maintains a Buy rating with a revised price target of $62, indicating an upside of approximately 85.45%.

  • Spyre Therapeutics (SYRE): Focused on treatments for inflammatory bowel disease, Spyre has been upgraded to a Buy with a price target of $64, suggesting a potential upside of around 88.33%.

[object Object]
Preview
9.5
11-05Newsfilter
LENZ Therapeutics Announces Financial Results and Key Developments for Q3 2025

  • FDA Approval and Launch: VIZZ (aceclidine ophthalmic solution) 1.44% received FDA approval for treating presbyopia, with a commercial launch initiated in October 2025 and broad availability expected by mid-Q4 2025.

  • Market Response: Over 2,500 eye care professionals (ECPs) have prescribed VIZZ, with 40% prescribing multiple times, leading to over 5,000 prescriptions filled by October 2025, indicating strong initial market acceptance.

  • Marketing Campaign: LENZ Therapeutics has partnered with Sarah Jessica Parker for a direct-to-consumer campaign set to launch in Q1 2026, aimed at increasing awareness and confidence in VIZZ among consumers.

  • Financial Overview: As of September 30, 2025, LENZ reported pro forma cash and equivalents of approximately $324 million, with significant increases in SG&A expenses due to the commercial launch preparations, while also noting a net loss of $16.7 million for Q3 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is LENZ Therapeutics Inc (LENZ) stock price today?

The current price of LENZ is 27.9 USD — it has decreased -0.36 % in the last trading day.

arrow icon

What is LENZ Therapeutics Inc (LENZ)'s business?

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

arrow icon

What is the price predicton of LENZ Stock?

Wall Street analysts forecast LENZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LENZ is 57.60 USD with a low forecast of 52.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is LENZ Therapeutics Inc (LENZ)'s revenue for the last quarter?

LENZ Therapeutics Inc revenue for the last quarter amounts to 12.50M USD, decreased % YoY.

arrow icon

What is LENZ Therapeutics Inc (LENZ)'s earnings per share (EPS) for the last quarter?

LENZ Therapeutics Inc. EPS for the last quarter amounts to -0.59 USD, increased 55.26 % YoY.

arrow icon

What changes have occurred in the market's expectations for LENZ Therapeutics Inc (LENZ)'s fundamentals?

The market is revising Upward the revenue expectations for LENZ Therapeutics, Inc. (LENZ) for FY2025, with the revenue forecasts being adjusted by 41.83% over the past three months. During the same period, the stock price has changed by -33.54%.
arrow icon

How many employees does LENZ Therapeutics Inc (LENZ). have?

LENZ Therapeutics Inc (LENZ) has 42 emplpoyees as of December 05 2025.

arrow icon

What is LENZ Therapeutics Inc (LENZ) market cap?

Today LENZ has the market capitalization of 872.99M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free